Editorial: Novel biomarkers in tumor immunity and immunotherapy.
作者信息
Matsutani Takaji, Akbay Esra, Elkord Eyad
机构信息
Translational Research Department, Drug Development Laboratories, Kyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
出版信息
Front Immunol. 2024 Apr 8;15:1405082. doi: 10.3389/fimmu.2024.1405082. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Novel biomarkers in tumor immunity and immunotherapy.社论：肿瘤免疫与免疫治疗中的新型生物标志物
Front Immunol. 2024 Apr 8;15:1405082. doi: 10.3389/fimmu.2024.1405082. eCollection 2024.
2
Special Issue "Cancer Immunotherapy: Tumor Microenvironment, Biomarker Discovery and Immune Resistance".特刊征稿：癌症免疫疗法：肿瘤微环境、生物标志物发现和免疫抵抗
Int J Mol Sci. 2024 May 8;25(10):5113. doi: 10.3390/ijms25105113.
3
Editorial: Endogenous danger signals in cancer immunology and immunotherapy.社论：癌症免疫学与免疫治疗中的内源性危险信号
Front Immunol. 2024 Jun 13;15:1438972. doi: 10.3389/fimmu.2024.1438972. eCollection 2024.
4
The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.癌症免疫治疗生物标志物学会工作组建议审查。
Semin Cancer Biol. 2018 Oct;52(Pt 2):12-15. doi: 10.1016/j.semcancer.2017.09.006. Epub 2017 Sep 22.
5
Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy.社论：增强抗肿瘤免疫的联合方法：聚焦免疫检查点阻断疗法
Front Immunol. 2019 Sep 6;10:2083. doi: 10.3389/fimmu.2019.02083. eCollection 2019.
6
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.癌症免疫治疗中STING通路的内源性和药理学靶向作用
Cytokine. 2016 Jan;77:245-7. doi: 10.1016/j.cyto.2015.08.258. Epub 2015 Aug 24.
7
Systemic immunity in cancer.癌症的系统性免疫。
Nat Rev Cancer. 2021 Jun;21(6):345-359. doi: 10.1038/s41568-021-00347-z. Epub 2021 Apr 9.
8
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.识别基线免疫相关生物标志物，预测免疫治疗的临床结局。
J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017.
9
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.肿瘤微环境中的免疫景观：对生物标志物开发和免疫治疗的影响。
Int J Mol Sci. 2020 Aug 1;21(15):5521. doi: 10.3390/ijms21155521.
10
[Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].肿瘤内B细胞和三级淋巴结构是生存和免疫治疗反应的生物标志物
Bull Cancer. 2020 Apr;107(4):403-404. doi: 10.1016/j.bulcan.2020.02.008. Epub 2020 Apr 10.
引用本文的文献
1
Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy.肿瘤相关巨噬细胞：极化、免疫调节与免疫治疗
Cells. 2025 May 19;14(10):741. doi: 10.3390/cells14100741.
2
Prognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors.生物标志物在原发性纵隔大B细胞淋巴瘤中的预后影响：免疫检查点抑制剂早期整合的理论依据
Explor Target Antitumor Ther. 2025 May 20;6:1002318. doi: 10.37349/etat.2025.1002318. eCollection 2025.
Zotero 插件